UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): January 5, 2000
MOLECULAR BIOSYSTEMS, INC.
(Exact name of registrant as specified in its charter)
Delaware 1-10546 36-3078632
(State of Incorporation) (Commission File Number) (I.R.S. Identification No.)
10030 Barnes Canyon Road, San Diego, California 92121
(Address of principal executive offices)
Registrant's telephone number, including area code: (858) 812-7001
<PAGE>
Item 5. Other Events
Molecular Biosystems to be Quoted on the NASD Over-The-Counter Bulletin Board.
Effective January 5, 2000, trading of Molecular Biosystems, Inc. (the
"Company") common stock was moved to the NASD Over-The-Counter Bulletin Board. A
new trading symbol of "MBIO" was assigned to the Company by NASD. The Company
had previously traded on the New York Stock Exchange under the symbol "MB"
through the close of business January 4, 2000.
Item 7. Financial Statements and Exhibits
10.1 Press release dated December 28, 1999.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
MOLECULAR BIOSYSTEMS, INC.
/s/ Elizabeth Hougen
Elizabeth Hougen
Executive Director, Finance and Chief Financial Officer
(Principal Financial and Accounting Officer)
1/6/00
<PAGE>
Exhibit Index
Exhibit Description
10.1 Press release dated December 28, 1999.
<PAGE>
Exhibit 10.1
Contacts:
Elizabeth Hougen, Chief Financial Officer (858) 812-7179
Patricia Sullivan, Manager, Investor Relations (858) 812-7146
E-Mail: [email protected]
MBI Plans for Listing on NASD's
Over-The-Counter Bulletin Board
San Diego, California, December 28, 1999 - Molecular Biosystems, Inc. announced
today that trading of its common stock will continue on the New York Stock
Exchange until the close of business on Tuesday, January 4, 2000. The date was
extended from December 30, 1999, in order to effectuate an orderly transition.
Effective Wednesday, January 5, 2000, MBI's common stock is expected to be
quoted on NASD's Over-The-Counter Bulletin Board. A trading symbol will be
assigned when listing commences.
MBI, based in San Diego, California, is a world leader in developing contrast
agents for diagnostic imaging. Its innovative product, OPTISON(R), improves
diagnosis of heart disease through clearer ultrasound images.
This news release contains forward-looking statements that involve risks and
uncertainties. Among the factors that could result in a materially different
outcome are: MBI's failure to be quoted on NASD's Over-The-Counter Bulletin
Board and other risk factors reported from time to time in MBI's filings with
the Securities and Exchange Commission.
For More Information on Molecular Biosystems by Fax, Dial 888-329-4007,
or Visit its Web site: www.mobi.com
